Trending Topic

20 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as T2D, using non-invasive biomarkers. This article explores the rationale to screen for advanced fibrosis in people with risk […]

10 mins

José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 29th 2022

In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be.

The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility Trials was presented at the 22nd Annual Diabetes Technology Meeting, 03-05 Nov, 2022.

Questions:

  1. Could you give us a brief overview of the RocketAP and its advantages over other artificial pancreas’ (APs)? (0:25)
  2. What have you learned through feasibility studies of the RocketAP? (4:49)
  3. How does the RocketAP compare to the USS-Virginia system in terms of time in range? (6:05)
  4. What will be the next steps in the clinical development of the Rocket AP? (8:21)

Disclosures: José García-Tirado discloses grant/research support from Dexcom.

Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.

Recorded as a highlight of DTM 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup